Navigation Links
Inclusion of Six-Year Overall Survival Data in the Eloxatin(R) (oxaliplatin injection) Prescribing Information Granted FDA Priority Review
Date:2/20/2008

- Review Based on MOSAIC Clinical Trial Demonstrating Significantly Improved Six-year Overall Survival in Stage III Colon Cancer Following

Surgery Compared to Standard Regimen Alone -

BRIDGEWATER, N.J., Feb. 20 /PRNewswire-FirstCall/ -- Sanofi-aventis today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and assigned priority review status to a supplemental new drug application (sNDA) that proposes changes to the Eloxatin(R) (oxaliplatin injection) prescribing information (PI) to include a six-year analysis from the MOSAIC trial. In the proposed PI changes, sanofi-aventis is seeking the inclusion of six-year overall survival and five-year disease free survival data in Stage III colon cancer patients treated with either FOLFOX4 (Eloxatin- based chemotherapy regimen) or standard infusional 5-FU/LV-based chemotherapy alone, following surgery to remove the primary tumor.

A priority review designation sets the target date for the completion of the FDA's review of the proposed changes at or before six months from the date of filing.

"We are pleased that FDA is giving priority review to our application for a label change to include updated six-year overall survival data," said Dr. Nassir Habboubi, Vice President of U.S. Medical Affairs, Oncology, for sanofi- aventis. "Inclusion of these data in the prescribing information would provide physicians with a more updated analysis than the existing PI and will help them better evaluate the use of prescribing an Eloxatin(R)-based chemotherapy regimen for their Stage III colon cancer patients."

In the MOSAIC trial, Stage III colon cancer patients treated after complete surgical resection of the tumor with Eloxatin in combination with infusional 5-FU/LV had a significant reduction (20%) in the risk of dying after a median of six years compared to standard 5FU/LV-based chemotherapy alone (hazard ratio of 0.80, confidence interval [0.65, 0.97],
'/>"/>

SOURCE sanofi-aventis
Copyright©2008 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3

Related medicine technology :

1. Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS)
2. Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
3. Positive Xeloda(R) Five-Year Overall Survival Study Data in the Adjuvant Treatment of Colon Cancer Presented at Leading European Cancer Meeting
4. IDM Pharma Announces Updated Phase 3 Mifamurtide (L-MTP-PE) Data Confirms Statistically Superior Overall Survival in Osteosarcoma Patients
5. Soliris(R) Demonstrates Reductions in Hemolysis and Improvements in Fatigue, Overall Quality of Life and Anemia in a Broad Population of PNH Patients
6. Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkins Lymphoma
7. Outcomes Vary for Prostate Cancer Patients Choosing Surgery; Overall, No Treatment Proven Superior
8. Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival
9. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
10. ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study
11. First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)OMAHA, Neb., Dec. 4 Amber Pharmacy announced today that it received accreditation by the Accreditation Commission for Health Care, Inc. (ACHC) for specialized pharmacy services. For nearly 15 years,
(Date:12/4/2009)DURHAM, N.C., Dec. 4 Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBT) today announced that the first patient has been enrolled in the company,s Phase II-b, dose escalation, clinical trial in S
(Date:12/4/2009)STREAMWOOD, Ill., Dec. 4 Shared Imaging, LLC, an independent provider of CT, MRI and PET/CT systems and service programs for hospitals and healthcare providers, is excited to announce it has received
Breaking Medicine Technology:Amber Pharmacy Earns Accreditation From ACHC 2Oxygen Biotherapeutics, Inc. Enrolls First Patient in Traumatic Brain Injury Clinical Trial in Switzerland 2Shared Imaging Earns The Joint Commission's Accreditation for Ambulatory Health Care 2Amarex Clinical Research Selects OmniComm Systems to Provide eClinical Solutions for Phase III Medical Device Study and Joins OmniComms CRO Preferred 4865 1Amarex Clinical Research Selects OmniComm Systems to Provide eClinical Solutions for Phase III Medical Device Study and Joins OmniComms CRO Preferred 4865 2Amarex Clinical Research Selects OmniComm Systems to Provide eClinical Solutions for Phase III Medical Device Study and Joins OmniComms CRO Preferred 4865 3The Blue Foundation for a Healthy Florida Receives Grant to Address National Regional Nursing Shortages 54735 1The Blue Foundation for a Healthy Florida Receives Grant to Address National Regional Nursing Shortages 54735 2The Blue Foundation for a Healthy Florida Receives Grant to Address National Regional Nursing Shortages 54735 3The Blue Foundation for a Healthy Florida Receives Grant to Address National Regional Nursing Shortages 54735 4The Blue Foundation for a Healthy Florida Receives Grant to Address National Regional Nursing Shortages 54735 5Laureate Pharma Elects New Board Member 13606 1Laureate Pharma Elects New Board Member 13606 2
...nced Cancer Patients, ROCKVILLE, Md., April 9, 20...age pharmaceutical company developing,therapeutics...ases, today,announced that it has commenced a Phas...e inhibitor, ENMD-2076, in advanced cancer patient...ancer Center, will serve as,co-principal investiga...
...tivity of CR011-vcMMAE for ...results to be presented in June at 2008 ASCO ... Conn., April 9, 2008 CuraGen,Corporation (Nasdaq...any,focused on oncology, announced today that it h...te (ADC), into Phase II for the treatment of patie...
Other Medicine Technology:EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program 2EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program 3EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program 4CuraGen Advances CR011-vcMMAE into Phase II 2CuraGen Advances CR011-vcMMAE into Phase II 3CuraGen Advances CR011-vcMMAE into Phase II 4
(Date:12/4/2009)PALO ALTO, Calif., Dec. 4 Varian Medical Systems (NYSE: VAR ) announced today that its Board of Directors has set the regular 2010 Annual Meeting of Stockholders for February 11, 2010 with a record
(Date:12/4/2009)PEMBROKE, Bermuda, Dec. 4 Allied World Assurance,Company Holdings, Ltd (NYSE: AWH ) today announced that Scott Carmilani,President and Chief Executive Officer, and Jack Sennott, Executive Vice,Pres
(Date:12/4/2009)MADISON HEIGHTS, Mich., Dec. 4 The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Allergan, Inc. (NYSE: AGN ) as its February 2010 "Stock to Stud
(Date:12/4/2009)Late recurrence is a risk for some pediatric cancers, particularly Ewing sarcomas and tumors of the central nervous system, according to a new study published online December 4 in the Journal of the
(Date:12/4/2009)More than 15 million Americans are recruited annually to participate in clinical trials according to the Alliance for Human Research Protection (AHRP), and most will be compensated for their participa
Breaking Medicine News(10 mins):Health News:Varian Medical Systems Schedules Annual Stockholder Meeting in Palo Alto 2Health News:Allied World to Present at the 2009 Goldman Sachs U.S. Financial Services Conference 2Health News:BetterInvesting Magazine Releases February Stock to Study and Undervalued Stock Choicesfor Investors' Informational and Educational Use 2Health News:Human guinea pigs wary of high-paying medical trials 2
...tudy of its kind, a Mexican health care program cr... crippling health care costs among poorer househol...Popular program, and arise from an evaluation cond... establish that the program achieved its main goal...
...th in Long-Term Survivors of Hereditary Retinoblas...stoma are at an increased risk of death due to a s... Retinoblastoma is a very rare cancer of the eye ...he risk of death due to these subsequent cancers i...
...te have found that the growth factor known as TGF-... in the retina and that blocking it can cause reti...April 2 issue of PLoS ONE , may have an important...hey add to our understanding of the molecules that...
...ement of these growths needs to be tailored , ...e cancer cell can lead to multiple, anatomically d...e types of tumors usually look similar, but, until...dy by a team at the Indiana University School of M...
...e interventions in future, study finds , ,...ve treatment in the first two years after a diagno...ove patient survival, a new study finds. , Researc...ceived the most intensive treatment was $7,131 com...
...nd should be urged, expert says, , , TUESD...of moderate exercise will not harm people with hea... a new study has found. , That admittedly tepid co...e. , Some were started on a 36-session training pr...
Other Medicine News:Health News:Mexican health care program successful at reducing crippling health care costs 2Health News:Mexican health care program successful at reducing crippling health care costs 3Health News:Also in the April 7 JNCI 2Health News:Also in the April 7 JNCI 3Health News:Also in the April 7 JNCI 4Health News:Growth factor TGF-B helps maintain health of retinal blood vessels 2Health News:Single Cell May Produce Multiple Lung Cancer Tumors 2Health News:Intensive Early Treatment Doesn't Help Bladder Cancer Survival 2Health News:Exercise Might Benefit Some With Heart Failure 2Health News:Exercise Might Benefit Some With Heart Failure 3
MONOJECT Red/Yellow Mottled Stopper
MONOJECT Black Stopper
VACUETTE Paediatric Fluoride Tubes - Ridged (safety screw cap)
BD Vacutainer® Fluoride Tubes - Plastic
Medicine Products: